Profile data is unavailable for this security.
About the company
Werewolf Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. It is leveraging its PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Its product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and IL-12 INDUKINE molecules for the treatment of solid tumors. WTX-124 is in development as a monotherapy and in combination with pembrolizumab in multiple solid tumor types. WTX-330 is in development as a single agent in metastatic solid tumors and non-Hodgkin lymphoma. Its pipeline also includes JZP898 and WTX-712.
- Revenue in USD (TTM)16.22m
- Net income in USD-41.58m
- Incorporated2017
- Employees46.00
- LocationWerewolf Therapeutics Inc200 Talcott Avenue, 2Nd FloorWATERTOWN 02472United StatesUSA
- Phone+1 (617) 952-0555
- Fax+1 (302) 655-5049
- Websitehttps://werewolftx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| I-Mab ADR | 3.82m | -202.46m | 152.06m | 220.00 | -- | 0.6393 | -- | 39.82 | -2.43 | -2.43 | 0.0459 | 2.94 | 0.0083 | -- | -- | 17,357.28 | -43.84 | -35.99 | -53.14 | -42.08 | 100.00 | -- | -5,302.03 | -496.71 | -- | -42.63 | 0.0171 | -- | 112.48 | -12.46 | 41.54 | -- | -4.66 | -- |
| OptiNose Inc | 74.02m | -30.75m | 154.98m | 132.00 | -- | -- | -- | 2.09 | -0.2733 | -0.2733 | 0.659 | -0.8777 | 0.7453 | 0.8764 | 4.74 | 560,772.80 | -30.91 | -48.25 | -- | -98.95 | 88.98 | 86.96 | -41.47 | -131.66 | 2.17 | -1.16 | 4.16 | -- | -6.93 | 58.64 | 52.58 | -- | -27.96 | -- |
| Kodiak Sciences Inc | 0.00 | -232.75m | 156.03m | 107.00 | -- | 0.6468 | -- | -- | -4.44 | -4.44 | 0.00 | 4.59 | 0.00 | -- | -- | 0.00 | -43.30 | -31.73 | -47.44 | -33.61 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 21.97 | -- | 134.76 | -- |
| Adverum Biotechnologies Inc | 0.00 | -112.90m | 156.09m | 121.00 | -- | 0.8562 | -- | -- | -10.23 | -10.23 | 0.00 | 8.78 | 0.00 | -- | -- | 0.00 | -41.55 | -36.39 | -47.50 | -39.04 | -- | -- | -- | -5,279.60 | -- | -- | 0.00 | -- | -- | 17.43 | 24.18 | -- | -0.0247 | -- |
| Telomir Pharmaceuticals Inc | 0.00 | -18.84m | 156.34m | 1.00 | -- | 51.83 | -- | -- | -0.6889 | -0.6889 | 0.00 | 0.1019 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -0.8986 | 0.00 | -- | -- | -- | -1,430.39 | -- | -- | -- |
| CervoMed Inc | 9.49m | -593.84k | 157.07m | 8.00 | 9.64 | 22.00 | -- | 16.55 | 1.97 | 1.97 | 2.04 | 0.8648 | 0.719 | -- | -- | 1,186,515.00 | -4.50 | -53.67 | -5.49 | -58.89 | -- | -- | -6.26 | -949.54 | -- | -- | 0.00 | -- | -- | -- | 86.07 | -- | -- | -- |
| Mediwound Ltd | 19.85m | -12.75m | 157.64m | 100.00 | -- | 6.95 | -- | 7.94 | -1.38 | -1.38 | 2.15 | 2.44 | 0.303 | 5.64 | 5.07 | 198,510.00 | -19.46 | -24.48 | -25.65 | -32.92 | 16.92 | 43.27 | -64.24 | -38.43 | 1.83 | -- | 0.218 | -- | -29.48 | 40.60 | 65.73 | -- | 64.66 | -- |
| Werewolf Therapeutics Inc | 16.22m | -41.58m | 158.18m | 46.00 | -- | 1.34 | -- | 9.75 | -1.09 | -1.09 | 0.4343 | 2.72 | 0.087 | -- | 4.61 | 345,127.70 | -22.31 | -- | -25.22 | -- | -- | -- | -256.33 | -- | -- | -- | 0.2511 | -- | 21.60 | -- | 30.56 | -- | -- | -- |
| Sagimet Biosciences Inc | 2.00m | -27.92m | 160.21m | 10.00 | -- | 0.8431 | -- | 80.10 | -1.23 | -1.23 | 0.0862 | 5.95 | 0.018 | -- | -- | 200,000.00 | -25.18 | -- | -26.34 | -- | -- | -- | -1,395.90 | -- | -- | -- | 0.00 | -- | -- | -- | 8.60 | -- | -- | -- |
| Seres Therapeutics Inc | 126.85m | -82.68m | 162.05m | 233.00 | -- | -- | -- | 1.28 | -0.6062 | -0.6062 | 0.9495 | -0.3945 | 0.4149 | -- | -- | 544,407.80 | -27.04 | -41.51 | -36.82 | -54.13 | -- | -- | -65.18 | -170.14 | 1.25 | -9.21 | 2.41 | -- | 1,672.24 | 34.91 | 54.54 | -- | 32.72 | -- |
| ProQR Therapeutics NV | 14.67m | -29.20m | 162.71m | 157.00 | -- | 4.45 | -- | 11.09 | -0.3597 | -0.3597 | 0.1807 | 0.4496 | 0.0957 | -- | -- | 93,453.45 | -18.83 | -35.51 | -23.01 | -40.51 | -- | -- | -196.75 | -926.31 | -- | -- | 0.3557 | -- | 118.51 | 10.58 | 56.35 | -- | 34.45 | -- |
| Alimera Sciences Inc | 90.22m | -22.66m | 162.93m | 159.00 | -- | 4.01 | -- | 1.81 | -1.57 | -1.57 | 2.42 | 0.7762 | 0.8989 | 7.11 | 3.43 | 567,415.10 | -21.34 | -19.08 | -25.84 | -27.37 | 86.52 | 86.80 | -23.74 | -19.55 | 2.51 | -0.0756 | 0.6323 | -- | 49.19 | 11.62 | -18.14 | -- | 236.53 | -- |
| Acumen Pharmaceuticals Inc | 0.00 | -55.94m | 164.02m | 51.00 | -- | 0.6259 | -- | -- | -1.05 | -1.05 | 0.00 | 4.36 | 0.00 | -- | -- | 0.00 | -22.89 | -- | -23.72 | -- | -- | -- | -- | -- | -- | -- | 0.1034 | -- | -- | -- | -22.20 | -- | -- | -- |
| P3 Health Partners Inc | 1.35bn | -67.27m | 164.38m | 400.00 | -- | 0.4236 | -- | 0.1215 | -0.5855 | -0.5855 | 11.86 | 1.23 | 1.57 | -- | 11.40 | 3,381,965.00 | -21.31 | -- | -90.11 | -- | 1.59 | 0.1781 | -13.57 | -56.93 | -- | -10.05 | 0.2368 | -- | 20.67 | 70.58 | 78.61 | -- | -11.20 | -- |
Data as of Jun 07 2024. Currency figures normalised to Werewolf Therapeutics Inc's reporting currency: US Dollar USD
47.18%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 24 May 2024 | 6.14m | 14.38% |
| PFM Health Sciences LPas of 31 Mar 2024 | 3.01m | 7.04% |
| Adage Capital Management LPas of 31 Mar 2024 | 3.00m | 7.02% |
| Janus Henderson Investors US LLCas of 31 Mar 2024 | 1.69m | 3.95% |
| Rubric Capital Management LPas of 31 Mar 2024 | 1.62m | 3.79% |
| BofA Securities, Inc.as of 31 Mar 2024 | 1.39m | 3.25% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 1.10m | 2.57% |
| Monashee Investment Management LLCas of 31 Mar 2024 | 890.00k | 2.08% |
| Eagle Health Investments LPas of 31 Mar 2024 | 700.00k | 1.64% |
| Sphera Funds Management Ltd.as of 31 Mar 2024 | 626.81k | 1.47% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
